Back to Results

Iterum Therapeutics PLC (ITRMF)

Iterum Therapeutics plc is a healthcare company focused on developing and commercializing therapies for drug-resistant bacterial infections in Ireland, Bermuda, and the United States. Its marketed product is ORLYNVAH, an oral penem antibiotic used for uncomplicated urinary tract infections in adult women caused by specified bacteria when treatment alternatives are limited or unavailable. The company is also advancing sulopenem, an anti-infective candidate available in oral and intravenous forms, for a range of bacterial infections including urinary tract, intra-abdominal, respiratory, and certain urogenital indications. Founded in 2015 and headquartered in Dublin, Ireland, Iterum Therapeutics plc is currently in reorganization.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-ITRM.F
—
—
—
$9 39,030.4% Upside
—
Bargain
Weak
—
—
—
0.0%
August 7, 2026
-0.1x
-0.2x
3.7x
1.215 M
24.16 M
96.5%
99.2%
-123.2
—
72.4%
Valuation • Fair Value

Iterum Therapeutics PLC (OTC-ITRM.F) Fair Value by Valuation Model

Compare the primary fair value estimate for Iterum Therapeutics PLC (OTC-ITRM.F) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

$9 39,030.4% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Iterum Therapeutics PLC (OTC-ITRM.F) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Iterum Therapeutics PLC (OTC-ITRM.F)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

390 K

Current operating scale indicator.

Revenue Forecast

800 K

Forward revenue estimate.

EBITDA

-19.324 M

Current operating profitability reference.

EBITDA Forecast

-22.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Iterum Therapeutics PLC (OTC-ITRM.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Iterum Therapeutics PLC (OTC-ITRM.F)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-123.2

Lower score that deserves closer risk review.

FCF / Net Income

72.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Iterum Therapeutics PLC (OTC-ITRM.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Iterum Therapeutics PLC (OTC-ITRM.F)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 7, 2026

Days to Earnings

17

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Iterum Therapeutics PLC (OTC-ITRM.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Iterum Therapeutics PLC (OTC-ITRM.F) Stock Forecast & Technical Outlook

Review Iterum Therapeutics PLC (OTC-ITRM.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Iterum Therapeutics PLC (OTC-ITRM.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Iterum Therapeutics PLC (OTC-ITRM.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Iterum Therapeutics PLC (OTC-ITRM.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Iterum Therapeutics PLC (OTC-ITRM.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Iterum Therapeutics PLC (OTC-ITRM.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Iterum Therapeutics PLC (OTC-ITRM.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Iterum Therapeutics PLC (OTC-ITRM.F) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Iterum Therapeutics PLC (OTC-ITRM.F) Stock FAQ

Quick answers about Iterum Therapeutics PLC (OTC-ITRM.F) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
Not available
Data is currently unavailable
Valuation Rating
Not available
Classification is not available
Analyst Target
$9 39,030.4% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

A fair value estimate for Iterum Therapeutics PLC (OTC-ITRM.F) is not currently available in the latest data file.

A clear undervalued or overvalued classification is not currently available in the latest data file.

The available analyst price target for Iterum Therapeutics PLC (OTC-ITRM.F) is $9 39,030.4% Upside.

The current financial health read for Iterum Therapeutics PLC (OTC-ITRM.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Iterum Therapeutics PLC (OTC-ITRM.F) is August 7, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Iterum Therapeutics PLC (OTC-ITRM.F) is -0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Iterum Therapeutics PLC is 1.215 M.

The current enterprise value listed for Iterum Therapeutics PLC is 24.16 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Iterum Therapeutics PLC is OTC-ITRM.F, and the stock is listed on OTC Markets.

Iterum Therapeutics PLC (OTC-ITRM.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Iterum Therapeutics PLC is 96.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Iterum Therapeutics PLC is 99.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)